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Abstract
Background: Cardio toxicity due to interferon therapy was reported only in small case series or case reports. The
most frequent cardiac adverse effects related to interferon are arrhythmias and ischemic manifestations. The
cardiomyopathy and pericarditis are rare but can be life threatening. The predisposing factors for interferon cardio
toxicity were described only for ischemic manifestations and arrhythmias.
Case presentation: The authors report a case of pericarditis due to alpha interferon therapy for chronic hepatitis
C, in a young woman without previous cardiac pathology. The clinical manifestations started during the 7-th
month of interferon treatment. The cessation of interferon was necessary. After interferon discontinuation the
patient recovered, with complete resolution of pericarditis. The patient scored 9 points on the Naranjo ADR
probability scale, indicating a very probable association between pericarditis and interferon administration.
Conclusion: If a patient receiving interferon therapy complains of chest pain of sudden onset, a cardiac ultrasound
should be performed in order to rule out pericarditis. We point out the possibility of an infrequent but severe
adverse effect of interferon therapy.
Background
Pegylated interferon plus ribavirin represents the gold
standard therapy for hepatitis C virus (HCV) but various
side effects may occur, limiting its efficacy [1,2].
Although some of these adverse effects are rarely
reported, their severity can be higher than expected,
sometimes leading to a life-threatening event. The diver-
sity of the described adverse effects may increase
because of the high number of patients who receive
treatment for HCV hepatitis. Their monitoring and
reporting is important in order to facilitate subsequent
recognition of similar cases.
We report a case of acute pericarditis without tampo-
nade which was correlated with pegylated interferon
alpha 2a treatment for chronic HCV hepatitis.
Case Presentation
A 38-year-old white female, without previous cardiac
pathology, was being monitored and treated for chronic
HCV hepatitis, genotype I virus. She was started on a
combination treatment with peginterferon alpha 2a
(180 μg weekly) and ribavirin (1000 mg daily, according
to her body weight). The patient had complete early
virologic response (HCV-RNA was undetectable at
12 weeks of treatment). In the first seven months of
treatment no severe side effects (hematologic, endocrine,
ophthalmic or autoimmune) were observed.
In the 7th month of treatment the patient accused
chest pain, dry cough, fatigue, dyspnea, without fever
and she presented herself to the emergency room.
On physical examination we found: tachypnea (22-24/
min), tachycardia (96/min), a blood pressure of 100/70
mmHg with pulmonary and abdominal examination
within the normal limits. Cardiac examination revealed
a third heart sound over the precordium as well as
muffled cardiac sounds. The pulmonary X-ray was nor-
mal and the ECG showed no specific repolarisation
abnormalities. Trans-thoracic cardiac ultrasonography
revealed a pericardial effusion without tamponade.
Laboratory data revealed: mild leukopenia, anemia,
thrombocytopenia (which didn’t need reduction of inter-
feron or ribavirin doses), minor biological inflammatory
syndrome (CRP - 17 mg/l). The hepatic enzymes were
normal, HCV-RNA was undetectable, serological tests
for viruses and bacteria which could have explained the
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pericarditis were negative: ECHO, Coxsackie, adeno-
virus, influenza virus, parainfluenza virus, EBV, CMV,
HIV, Mycoplasma pneumoniae, Chlamydia pneumoniae,
Rickettsia spp, Legionella pneumophila, Borrelia burg-
dorferii. Serological tests for viruses remained negative
for the following 2 weeks. Quantiferon TB gold was
negative. The patient didn’t receive antimycobacterial
medication. The ASO titer was in the normal range.
Autoimmune tests were performed, with negative anti-
nuclear factor, anti-DNA antibodies, p ANCA, c ANCA,
anti-mitochondrial antibody, anti-Ro and anti-La antibo-
dies and negative cryoglobulinemia. Thyroid function
tests were normal, and anti tyreo-peroxidase antibodies
were absent.
The antiviral medication was stopped and the patient
received ibuprofen. The symptoms disappeared and the
pericardial effusion resolved in 15 days.
Because the patient was infected with genotype 1 virus
and detection of HCV-RNA at 4 weeks of treatment was
not performed (in order to confirm a rapid virological
response), the antiviral treatment was restarted only
with pegylated interferon. After the first dose of inter-
feron administration symptoms reappeared. The echo-
cardiography showed an increase of pericardial fluid (at
24 hours after interferon administration). The antiviral
medication was stopped again with rapid recovery.
Six months after discontinuation of treatment, the
HCV-RNA was undetectable (the patient had sustained
virologic response).
The correlation of pericarditis with interferon adminis-
tration was appreciated, for the presented case using the
Naranjo ADR probability scale, which summed up 9
points, indicating a very probable association (table 1) [3].
Discussion
Interferon plays an essential role in the mechanisms of
defense against infections, being produced by a variety
of cells. Until now two types of interferon have been
identified: type I (alpha and beta interferon), which
blocks the translation and viral replication and type II
(gamma interferon), which initiates the synthesis of che-
mical substances with antiviral properties [4]. On top of
the positive effects, the administration of interferon can
be associated with many unwanted adverse effects
because of the destruction of uninfected cells. The pre-
valence of life threatening complications during the
interferon treatment is less then 1%. The cardio toxicity
of interferon has been even rarely reported, only in
small series of patients, and often just in isolated cases
[5]. Among the three types of interferon, the alpha
interferon is the most cardio toxic, followed by beta and
gamma interferon.
The mechanism through which interferon is cardio
toxic has not been clearly demonstrated [6,7], but it is
presumed that at least two factors are implicated: the
deterioration of endothelial cells inducing the overlay of
immune complexes at this level; and stimulation of TNF
alpha, IL 2, IL 6, IL 1 release, that influence the vaso-
pressor response.
The most common cardio toxic clinical effects of
interferon are: arrhythmias- 58%, acute coronary syn-
drome- 21%, cardiomiopathies-12% and other manifesta-
tions - 9% (including pericarditis) [5]. There are no
described predisposing factors for interferon cardio
toxicity.
Acute pericarditis is determined by a multitude of
causes: infectious, neoplastic, uremia, autoimmune, trau-
matic, drug induced. Concerning drug toxicity, there
have been reported cases of acute pericarditis after the
administration of: hydralazine, procainamide, izoniazid,
phenylbutazone, dantrolene, doxorubicin, penicillin,
these situations being extremely rare. Interferon is not
cited by the ESC Guidelines on the Diagnosis and Man-
agement of Pericardial Diseases [8] as one of the causes
of drug induced pericarditis.
Acute pericarditis, as a consequence of interferon
treatment is extremely rare. So far, very few cases of
pericarditis related to administration of interferon have
been reported; some of these patients received inter-
feron for neoplastic diseases such as melanoma or acute
Table 1 NARANJO ADR PROBABILITY SCALE calculated for
our case summed up 9 points, indicating a very probable
association between acute pericarditis and interferon
treatment
Question Response Points
Are there previous conclusion reports on this
reaction?
Yes + 1
Did the adverse event appear after the suspect
drug was administered?
Yes +2
Did the AR improve when the drug was
discontinued or a specific antagonist was
administered?
Yes + 1
Did the AR reappear when drug was
readministered?
Yes + 2
Are there alternate causes [other than the
drug] that could solely have caused the
reaction?
No +2





Was the drug detected in the blood [or other
fluids] in a concentration known to be toxic?
No 0
Was the reaction more severe when the dose





Did the patient have a similar reaction to the
same or similar drugs in any previous
exposure?
No 0
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leukemia [9,10]. The role of ribavirin in the pathogenesis
of pericarditis could be considered. In our case, we
restarted only interferon therapy (after two weeks of dis-
continuation), which concluded in the reappearance of
pericardial effusion.
Six cases of pericarditis due to interferon alpha have
been reported in patients with chronic HCV hepatitis.
Three of these patients had an underlying pathology that
could explain the pericarditis: Sikole et al. reported a case
of pericarditis among hemodialysis patients receiving
interferon for hepatitis C [11], Suarez A et al described a
case of pericarditis in a patient with cryoglobulinemia
[12], Boonen et al. reported a case of pericarditis during
the treatment of chronic HCV hepatitis as part of a
lupus-like syndrome, with clinical manifestations of auto-
immune pathologies [13]. Recently Kazuahi Nishio et al
described a case of pericarditis related to pegylated inter-
feron therapy for HCV hepatitis. This patient had posi-
tive anti-DNA and anti-ds DNA IgM antibodies [14].
The case of pericarditis reported by Gressens B et al in
conjunction with the administration of interferon
occurred four months after stopping the treatment [15].
We are reporting a very rare adverse effect of pegylated
interferon treatment- acute toxic pericarditis, this being
the second case observed in a patient with no underlying
pathology, described in the medical literature. The first
case was reported by Wisniewski B et al; pericarditis
occurred in this case after the first dose of interferon [16].
In summary, we report a patient without any history
of cardiac disease who developed pericarditis after inter-
feron treatment. Reappearance of symptoms when the
antiviral treatment was restarted indicates a strong cor-
relation between drug and adverse effects [3]. The effect
of the virus itself is quite unlikely (undetectable HCV-
RNA). The clinical and biological markers of a possible
associated autoimmune pathology were absent. We
excluded a viral or bacterial (including tuberculosis)
etiology of pericarditis.
Conclusions
We consider that in a patient receiving interferon, peri-
carditis must be evoked if the patient accuses sudden
chest pain. It is of most importance that a cardiac ultra-
sound should be performed in a situation like this.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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